News

FTAI Infrastructure's Repauno Terminal Expansion Gains Approval

FTAI Infrastructure's Repauno Terminal Expansion Gains Approval

Exciting Development at Repauno Port and Rail Terminal

FTAI Infrastructure Inc. (NASDAQ: FIP) is thrilled to announce a key milestone in its growth journey as its subsidiary, Delaware River Partners LLC (DRP), has secured essential approval for the development of new underground storage caverns. This pivotal project, located along the picturesque Delaware River, holds significant promise for energy storage solutions and economic progress.

Overview of the New Underground Caverns

The New Jersey Department of Environmental Protection has granted DRP the green light to construct two state-of-the-art underground granite caverns designed to store liquefied petroleum gas (LPG), each boasting a remarkable capacity of over 600,000 barrels. This development comes as Repauno already operates an underground facility that can hold 180,000 barrels and is complemented by advanced ship loading capabilities and a modern rail transloading system. This ensures seamless connectivity between rail and vessel operations, making Repauno a competitive player in the energy market.

Strategic Importance of Repauno's Expansion

The construction of these underground caverns positions Repauno as a world-class energy hub. By securely storing energy sources more than 700 feet beneath the surface, it aims to enhance both local and international energy supply. This strategic expansion is vital, especially in light of the current limited import and export capacities in the region, allowing Repauno to significantly contribute to the energy independence goals of the United States.

Economic Impacts and Job Creation

Beyond its energy implications, the Repauno expansion project is set to deliver substantial economic benefits to the surrounding communities. DRP anticipates that the construction phase alone will generate over 500 well-paying jobs, vital for local workers and the economy. This job creation aligns with DRP's commitment to revitalizing the Delaware River industrial waterfront.

Leadership's Vision for Growth

“We are very excited to embark on this next phase of growth at Repauno,” expressed Hank Alexander, CEO of Delaware River Partners. He emphasizes that the expansion is designed to provide customers with efficient access to both domestic and international markets. The initiative not only promotes the production of valuable liquids but also aims to anchor continued job growth in the southern New Jersey area.

About FTAI Infrastructure Inc.

FTAI Infrastructure focuses on investing in critical infrastructure sectors that exhibit high barriers to entry, including rail, ports, terminals, and energy. These sectors collectively generate strong cash flows and foster opportunities for asset appreciation and earnings growth. Notably, FTAI Infrastructure is externally managed by Fortress Investment Group LLC, a diversified global investment firm known for its robust portfolio.

Frequently Asked Questions

What is the significance of the underground caverns at Repauno?

The new caverns will enhance storage capacity for liquefied petroleum gas, positioning Repauno as a key player in the energy sector and aiding in energy independence.

How many jobs will the construction of the new caverns create?

The construction project is expected to create over 500 local jobs, contributing positively to the economy.

What is the current capacity of the existing cavern at Repauno?

Repauno currently has an underground cavern capable of storing 180,000 barrels of liquefied petroleum gas.

Who manages FTAI Infrastructure Inc.?

FTAI Infrastructure is managed by an affiliate of Fortress Investment Group LLC, a leading investment firm.

What are FTAI Infrastructure's main investment areas?

FTAI Infrastructure primarily invests in infrastructure sectors including rail, ports, terminals, and power and gas, focusing on generating strong cash flows and growth potential.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

RYBREVANT's Promising Results in HNSCC Treatment

Updated Category News Views 115

Impressive Outcomes for RYBREVANT FASPRO in Head and Neck Cancer Tucked away in the endless cycle of drug trials, a glimmer of hope shines through with new data on RYBREVANT FASPRO in treating head and neck squamous cell carcinoma (HNSCC). This science talk might not rattle the ticker tape directly on NYSE:JNJ, but it has all the makings of a game-changer in the oncology...

Continue Reading
Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

Updated Category News Views 134

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...

Continue Reading
Sinclair Faces Labor Lawsuit for Break-time Violations

Updated Category News Views 175

Sinclair Television Caught in Labor Law Storm When you think of flaring tempers and boardroom brawls, you typically don't think of your everyday TV station. But right now, Sinclair Television of California, LLC is in the hot seat, accused of playing fast and loose with wage packets—specifically, allegedly denying meal periods and rest breaks that California labor laws...

Continue Reading
CapCut's Role in AI-Assisted Small Biz Marketing

Updated Category News Views 194

In today's fast-paced digital world, small businesses lament the constant hustle to stay relevant online. This juggling act with limited resources often makes effective marketing feel like a high-wire circus performance. Enter AI tools, promising to lighten the load, and CapCut stands out as a game-changer. AI Tools Revolutionizing Small Business Marketing Amid growing...

Continue Reading
Borr Drilling's Rig Sinks, Uncertainty Looms Offshore

Updated Category News Views 94

Unexpected Turn of Events at Sea Now here's a gut-punch nobody saw coming. Borr Drilling Limited (NYSE and OSE: BORR) got hit hard when their Prospector 5 drilling rig went under the waves offshore Gabon. This ain't no desk job dilemma; we're talking about a real-life offshore catastrophe. It all went down on October 24, 2026, when the rig experienced a punch through...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 361

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading
Innovent's IBI3001 Shows Promise in Phase 1 Trials

Updated Category News Views 279

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Continue Reading
Ping An's Bold Green Moves Ahead of APEC 2026

Updated Category News Views 175

Ping An's Pitch for Green: Talking the Talk and Walking the Walk? Well, here's something cooking in Shenzhen at the Ping An Finance Center—an international seminar championing green development initiatives. It's all buzz around Ping An Insurance (HKEX: 2318; SSE: 601318) flexing its green muscle, orchestrating conversations right before APEC 2026. Talk about timing....

Continue Reading
Gildan Activewear Faces Legal Battle Over Alleged Fraud

Updated Category News Views 151

Investor Alert: Gildan's Legal Showdown Alright, here's a twist you didn't see coming—or maybe you did if you've been tracking the ticker tapes like a hawk. Gildan Activewear Inc. (NYSE:GIL) is stuck in the kind of hot water that can scald the bottom line. The Stakes: Racing Towards December 14 Marked on your calendar, December 14, is a date of some significance if...

Continue Reading
Love Business Group Helps SMEs Navigate Broadband Choices

Updated Category News Views 88

Understanding Broadband Needs for UK SMEs When you're knee-deep in running a small biz in the UK, sorting out your broadband needs can feel like sifting through a thousand-piece puzzle. Enter Love Business Group, getting a nod of recognition for being the SME knight in shining armor. Aimed at businesses of all sizes, they've been pegged by Expert Consumers for helping...

Continue Reading

Top 5 Most Recently Viewed Articles

Exciting Developments in Entertainment and Technology This Week

Updated Category News Views 62

Weekly Highlights: Industry Updates You Can't Miss This week's press releases spotlight some pivotal changes that have reshaped various sectors, especially entertainment and technology. With numerous updates available, it can often feel overwhelming to stay informed. Here’s a detailed overview of the major stories that have caught our attention. Paramount Takes Action...

Continue Reading
Employee Assistance Programs: Resolving Issues Effectively

Updated Category News Views 175

Employee Assistance Programs Deliver Faster Resolution of Issues Based on a significant analysis of real-world Employee Assistance Program (EAP) counseling cases, this study investigates over 100,000 employee experiences spanning various organizations and demographics. The findings highlight how EAP counseling plays a vital role in addressing employee issues across...

Continue Reading
Treasury Bond Auction Results: Insights and Impact

Updated Category News Views 177

Auction Results Overview The recent auction of Treasury Bonds RIKB 28 1115 and RIKB 35 0917 brought substantial participation from investors. These auctions provide informative insights into market trends, reflecting demand and investor confidence in government securities. Key Auction Highlights In the latest treasury auction, the total amount allocated for RIKB 28 1115...

Continue Reading
See's Candies Spreads Holiday Cheer Nationwide Through Pop-Ups

Updated Category News Views 214

See's Candies Launches Festive Pop-Up Shops for Holidays The iconic American candy company, See's Candies, is making this holiday season sweet and memorable with its seasonal pop-up shops. Now celebrating over 100 years of tradition, this beloved chocolatier is stepping into various communities nationwide, bringing along its famous assortment of chocolates and treats....

Continue Reading
FDA Decision on Zepbound for Sleep Apnea Expected Soon

Updated Category Stocks Views 423

Eli Lilly Seeks FDA Approval for Zepbound in Sleep Apnea Treatment Eli Lilly has filed a U.S. application to treat obstructive sleep apnea (OSA) with its weight-loss medication Zepbound. Promising outcomes from two late-stage trials led to this action. The company wants to fill a big unmet need in sleep disorder therapies. Zepbound might give OSA sufferers a new choice if...

Continue Reading